文献速递前列腺癌

他汀类药物使用与启动雄激素剥夺治疗患者结局的关联

The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy.
PubMed 文献 · Eur Urol · 2020-12-31

本文为一项随机对照试验的事后二次分析,纳入1364例在接受根治性或挽救性放疗后启动雄激素剥夺治疗(ADT)的前列腺癌患者。中位随访6.9年,他汀使用与全因死亡(HR 0.64,95%CI 0.53-0.78,p<0.001)及前列腺癌特异性死亡(HR 0.65,95%CI 0.48-0.87,p=0.004)风险降低相关;至去势抵抗时间延长13%但未达统计学意义(p=0.15)。

要点

  • 他汀使用与ADT患者全因及前列腺癌特异性死亡风险降低相关
  • 至去势抵抗时间延长13%但无统计学意义(p=0.15)
  • 间歇ADT组他汀使用者停药时间有延长趋势(p=0.06)

核心结论

  • 在接受根治性或挽救性放疗后ADT治疗的前列腺癌男性中,他汀使用与总生存和前列腺癌特异性生存改善相关。
  • 间歇ADT患者中他汀使用与停药时间延长呈趋势相关。
  • 有必要开展他汀用于启动ADT男性的前瞻性试验。

研究设计与样本

  • 对一项比较间歇性雄激素剥夺(IAD)与连续性ADT的随机对照试验(NCT00003653)进行事后二次分析。
  • 纳入放疗后>1年前列腺特异性抗原(PSA)>3 ng/ml的患者,共1364例,其中他汀使用者585例(43%)。
  • 基线和研究期间他汀使用作为时间依赖协变量建模,模型校正年龄、放疗至ADT时间、基线PSA和既往ADT。

主要发现

  • 他汀使用者更年轻(72.7 vs 73.8岁,p=0.001),PSA>15 ng/ml比例更低(20% vs 25%,p=0.04)。
  • 中位随访6.9年,他汀使用与全因死亡风险降低相关(HR 0.64;95%CI 0.53-0.78,p<0.001)。
  • 他汀使用与前列腺癌特异性死亡风险降低相关(HR 0.65,95%CI 0.48-0.87,p=0.004)。
  • 他汀使用者至去势抵抗时间延长13%,但未达统计学意义(p=0.15)。
  • 探索性终点中,IAD组他汀使用者停药时间更长(中位0.85 vs 0.64年,p=0.06)。

关键数值与推荐

  • 主要终点为总生存。
  • 全因死亡HR 0.64(95%CI 0.53-0.78,p<0.001)。
  • 前列腺癌特异性死亡HR 0.65(95%CI 0.48-0.87,p=0.004)。
  • 至去势抵抗时间延长13%(p=0.15)。

临床怎么用

  • 提示在接受放疗后启动ADT的前列腺癌患者中,他汀使用可能与生存改善相关,但证据来自事后分析,不能据此常规处方他汀。
  • 对已因其他适应证使用他汀的ADT患者,可视为有利因素,但需结合个体情况。
  • 间歇ADT方案中他汀使用可能延长停药时间,值得在临床随访中关注。

局限性

  • 他汀使用者与非使用者之间可能存在残余混杂。
  • 存在适应证混杂(confounding by indication)。
  • 为随机对照试验的事后二次分析,非他汀随机分组,因果推断受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Studies have conflicting results regarding the association between statin use and biochemical recurrence for prostate cancer (PCa). A limited number of studies examining statins in advanced stages report positive results, with a few specifically examining statins and androgen deprivation therapy (ADT). OBJECTIVE: To perform a post hoc secondary analysis of a randomised controlled trial (RCT) of men initiating ADT to examine the association between statin use and outcomes. DESIGN, SETTING, AND PARTICIPANTS: Patients with prostate-specific antigen (PSA) >3 ng/ml >1 yr following primary/salvage radiotherapy were enrolled in an RCT of intermittent androgen deprivation (IAD) versus continuous ADT (NCT00003653). Baseline and on-study statin use was modelled as a time-dependent covariate. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was overall survival. Models were adjusted for age, time from radiotherapy to ADT, baseline PSA, and prior ADT. RESULTS AND LIMITATIONS: Of 1364 patients, statin users (585; 43%) were younger (72.7 vs 73.8 yr, p = 0.001) and less likely to have PSA >15 ng/ml (20% vs 25%, p = 0.04). After a median follow-up of 6.9 yr, statin use was associated with reduced overall (hazard ratio [HR]: 0.64; 95% confidence interval [CI] 0.53-0.78, p < 0.001) and PCa-specific (HR: 0.65, 95% CI 0.48-0.87, p = 0.004) mortality. Statin users had 13% longer time to castration resistance, but this did not reach statistical significance (p = 0.15). As an exploratory endpoint, in the IAD arm, statin users had longer time off treatment (median: 0.85 vs 0.64 yr, p = 0.06). Limitations include potential for residual confounding between statin users and nonusers, and confounding by indication. CONCLUSIONS: In men treated with ADT following primary or salvage radiotherapy, statin use was associated with improved overall and PCa-specific survival. In patients treated with IAD, statin use was associated with a trend towards longer time off treatment. A prospective trial of statins in men commencing ADT is warranted. PATIENT SUMMARY: We found a favourable association between statin use and survival outcomes in patients initiating androgen deprivation therapy.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Hamilton RJ, Ding K, Crook JM, et al. The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy. Eur Urol. 2020. PMID: 33390282. doi:10.1016/j.eururo.2020.12.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。